Physician profile
Dmitri Sivtsov
NPI 1467553958
$14,986.97
in general payments reported to CMS, 2019-2025
27 companies · $2,226 in 2025
The $2,226 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,232 · 2020: $1,449 · 2021: $2,096 · 2022: $2,464 · 2023: $1,786 · 2024: $1,733 · 2025: $2,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,731 · Education: $15.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,730.61 |
| Education | $15.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,995.20 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,623.33 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,413.06 | 2021-2025 | Vraylar |
| Bausch Health US, LLC | $1,213.91 | 2019-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $1,140.16 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $1,137.39 | 2019-2025 | Spravato |
| Lundbeck LLC | $1,083.20 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $1,030.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $912.20 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $656.81 | 2020-2025 | Caplyta |
| Allergan, INC. | $539.13 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $528.57 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $406.48 | 2019-2024 | Uzedy |
| Eisai INC. | $252.68 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $193.19 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $181.06 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $179.59 | 2022-2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $146.71 | 2019-2021 | |
| Shire North American Group INC | $88.58 | 2019 | |
| Alfasigma USA, INC. | $65.82 | 2020-2021 | |
| Almatica Pharma LLC | $57.59 | 2025 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $36.79 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.94 | 2025 | Cobenfy |
| Gilead Sciences, INC. | $21.97 | 2019 | |
| Janssen Scientific Affairs, LLC | $21.87 | 2023 | Invega Trinza, Spravato |
| Indivior INC. | $16.71 | 2020 | |
| Azurity Pharmaceuticals, INC. | $16.56 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitri Sivtsov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.